HOME
ABOUT US
JOIN MECFA
MEMBERS
OUR IMPACT
GIVE BREATH
NEWS
WHAT IS CF
MENU
Middle East CF Association
Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds
VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE
A case for improved carrier screening
Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis
CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics
The search for molecular glue in targeted disease control
Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says
Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p
MECFA Jordan Project report
Conquering chronic lung infection in cystic fibrosis patients
Bacteria diversity in airways increases during babies’ first year
CF patient 1st in US to undergo lung imaging with Xenoview
In Patients With CF on ETI, De-Escalating Other Therapy Did Not Affect Outcomes
MECFA supports Jordan CF charity with the help of Vertex
MECFA launches QI program in Jordan
Caregivers, Patients With Cystic Fibrosis, Primary Ciliary Dyskinesia at Elevated Risk of Mental Ill
Children with CF in Canada as young as age 1 OK’d for Orkambi
Nutrition for cystic fibrosis: how UAB is blazing new paths for patients